IRTC vs PACB Stock Comparison
PACB currently leads IRTC in this stock comparison, with AIQ scores of 48 vs 44. The clearest difference is momentum, while IRTC has the stronger quality profile.
What is the main difference between IRTC and PACB?
PACB leads the current stock comparison as Pacific Biosciences of California, Inc., with the clearest separation coming from momentum and the broader AIQ evidence mix.
AlgovestIQ AIQ Comparison
iRhythm Technologies, Inc. vs Pacific Biosciences of California, Inc.
PACB leads
PACB leads by 4 AIQ points, primarily on Momentum, having only recently taken the lead back from IRTC. Wall Street currently favors IRTC on target upside.
Fragile: 3 of 6 evidence groups support PACB, the lead recently changed hands, and its current signal state is conflicted.
iRhythm Technologies, Inc.
Pacific Biosciences of California, Inc.
The Algovestiq AIQ Score currently favors PACB over IRTC, 48 versus 44 as of Nov 18, 2026. PACB's advantage is driven primarily by stronger momentum, while IRTC holds the stronger quality profile. PACB also shows the stronger technical structure relative to its 50-day moving average, though analyst target upside currently favors IRTC. 3 of 6 covered evidence groups favor PACB today, and the comparison is rated Fragile on stability: the AIQ gap is narrow at 4 points. PACB lead: Reversed — IRTC led by 10 AIQ points 30 sessions ago; PACB now leads by 4.
Compare iRhythm Technologies, Inc. and Pacific Biosciences of California, Inc. across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.
Performance over time
Price return from daily closes; distributions are not included.
Price return comparison
Growth of $10,000, price only
Split-adjusted closes only. Distributions are excluded, which understates the return of any fund or stock that pays them.
Compare IRTC and PACB against another ticker
Open a multi-ticker workspace without changing this focused pair page.
AIQ Factor Divergence
Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.
- Momentum34 vs 84PACB +50
- Quality58 vs 32IRTC +26
- Value43 vs 23IRTC +20
- Risk Resilience44 vs 24IRTC +20
3 of 6 evidence groups favor PACB. PACB’s edge is concentrated in momentum; IRTC keeps a meaningful quality edge.
What changed since the last close
Latest scored session 2026-11-18, compared against the prior scored session 2026-11-17.
Largest factor move: Value -1, not enough on its own to move the overall score.
No signal started or stopped since the prior session; its 4 active signals are unchanged.
Largest factor move: Value -1, not enough on its own to move the overall score.
New signals
- Low Volume Rally Warning — bearish, volume, short horizon (0.56x)
- Stochastic Oversold Bounce — bullish, momentum, short horizon
PACB's lead was unchanged in the latest session.
Deeper signal detail for each name lives on its own signals page — IRTC and PACB both carry a full feed there.
The central trade-off
PACB (Pacific Biosciences of California, Inc.): the stronger current systematic profile, led by momentum.
IRTC (iRhythm Technologies, Inc.): the counter-case, on quality, value, risk resilience — but at materially higher volatility, 121.5% against 114.1%.
The AIQ Score and Wall Street therefore point in different directions on this pair.
Which one fits your objective
The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.
Balanced
PACBPACB on the overall AIQ Score, which weights Quality and Value most heavily.
Growth
PACBPACB on combined revenue and EPS growth.
Value
IRTCIRTC on the peer-relative Value factor, by 20 points.
Momentum
PACBPACB on the Momentum factor, by 50 points.
Lower downside
IRTCIRTC on Risk Resilience, by 20 points.
Analyst upside
IRTCIRTC on implied upside to the consensus price target.
AIQ vs Wall Street
The model and the Street disagree here: AIQ favors PACB, analyst targets favor IRTC. That disagreement is the most useful thing on this page.
| Measure | IRTC | PACB | Note |
|---|---|---|---|
| Implied upside to target | +86.6% | +5.2% | IRTC has more room |
| Target dispersion | +26% | +59.7% | Lower is tighter analyst agreement |
| Consensus | Buy | Hold | Context, not a primary driver |
| Analysts covering | 17 | 8 | Higher coverage generally improves confidence |
The two are measuring different things. The AIQ Score reads current fundamentals, valuation, trend and risk; analyst targets price forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something already priced in — it is worth resolving before acting on either.
Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.
AIQ Agreement Matrix
3 of 6 covered evidence groups favor PACB. A wide gap backed by one group is a weaker case than a narrow gap backed by five.
| Evidence group | Favors | Reading |
|---|---|---|
| AIQ Score | PACB | 44 vs 48 |
| Fundamentals | PACBon balance | revenue growth -1.2% vs 4%; EPS growth -89% vs 14.3%; TTM ROE -16.9% vs 61.7%; gross margin 72.3% vs 34.5%; operating margin -4.5% vs -99.6% — PACB takes 3 of 5 decided legs, not all of them |
| Valuation | IRTC | Value 43 vs 23 |
| Technicals | PACB | Price vs 50-day -15.1% vs -8.7%; vs 200-day -23.1% vs 22.4% |
| Risk Resilience | IRTC | Risk Resilience 44 vs 24 |
| Analyst expectations | IRTC | Target upside 86.6% vs 5.2% |
✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of IRTC and PACB and are excluded from the count.
AIQ Decision Stability
The conclusion is sensitive to small changes. Treat the lead as provisional and watch the flip conditions below.
- The AIQ gap is narrow at 4 points. (argues the conclusion is provisional)
- Only 3 of 6 covered evidence groups agree. (argues the conclusion is provisional)
- The lead has already changed hands inside the comparison window. (argues the conclusion is provisional)
- The leader is throwing conflicting signals. (argues the conclusion is provisional)
Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on PACB.
How the comparison changed
120 daily snapshots · Jun 1 – Nov 18PACB lead: Reversed — IRTC led by 10 AIQ points 30 sessions ago; PACB now leads by 4.
- Today
- PACB +4
- 44 vs 48
- 7 sessions ago
- IRTC +4
- 53 vs 49
- 30 sessions ago
- IRTC +10
- 54 vs 44
- 90 sessions ago
- IRTC +19
- 49 vs 30
The lead changed hands once in this window, most recently on Nov 13 when PACB moved ahead of IRTC.
AIQ Signal Divergence
Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.
0 bullish / 3 bearish / 1 neutral
Only IRTC
- Death Cross Active — bearish, trend, long horizon (7.01%)
- Downtrend Structure Active — bearish, trend, long horizon
- Keltner Channel Breakdown — bearish, volatility, short horizon
3 bullish / 3 bearish / 1 neutral, conflicted
Only PACB
- Golden Cross Active — bullish, trend, long horizon (25.22%)
- Beta Spike Warning — bearish, risk_regime, long horizon
- EMA Ribbon Expansion Bullish — bullish, trend, medium horizon
- Low Volume Rally Warning — bearish, volume, short horizon (0.56x)
- MACD Histogram Expanding Bearish — bearish, momentum, short horizon
- Stochastic Oversold Bounce — bullish, momentum, short horizon
Both carry 1 more signal that do not separate them: ATR Expansion - Breakout Mode.
PACB leads the comparison while carrying a conflicted signal state, which is one reason the stability rating is not higher.
Price vs model alignment
Whether the latest session's price move confirms what the model did over the same session, or contradicts it.
Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price +5.8%, AIQ 0 points).
Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price +0.55%, AIQ 0 points).
What would flip this result
A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.
- 1IRTC closes the Momentum gap — currently 50 points behind, the largest single contributor to PACB's edge.
- 2IRTC's Death Cross Active resolves — a bearish trend rule currently active against it.
- 3PACB's conflicting signal state resolves bearish — it currently carries 3 bullish and 3 bearish rules at once.
- 4A market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.
The full evidence
Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.
Fundamentals
PACB leads on balance| Metric | IRTC | PACB |
|---|---|---|
| Revenue growth (YoY) | -1.2% | 4% |
| EPS growth (YoY) | -89% | 14.3% |
| Gross margin | 72.3% | 34.5% |
| Operating margin | -4.5% | -99.6% |
| Return on equity (TTM) | -16.9% | 61.7% |
| Debt to equity | 4.1 | -11.49 |
Performance
PACB leads 5 of 6 windows| Metric | IRTC | PACB |
|---|---|---|
| 1 week (5 sessions) | 1.9% | -13.1% |
| 1 month (20 sessions) | -15.4% | 13.3% |
| 3 months (63 sessions) | -21.4% | 62% |
| 6 months (126 sessions) | -19.4% | 75% |
| Year to date | -48.2% | 4.8% |
| 1 year (252 sessions) | -48.7% | 12.6% |
Technicals
PACB has the stronger structure| Metric | IRTC | PACB |
|---|---|---|
| RSI (14) | 35.3 | 43.1 |
| ADX (14) | 32 | 27.4 |
| Price vs 50-day | -15.1% | -8.7% |
| Price vs 200-day | -23.1% | 22.4% |
| Volatility (1M, annualized) | 121.5% | 114.1% |
Risk
IRTC is the more resilient| Metric | IRTC | PACB |
|---|---|---|
| Beta | 0.5 | 2.1 |
| Sharpe ratio | -0.91 | 0.61 |
| Sortino ratio | -1.11 | 0.96 |
| Max drawdown | -54.5% | -58.4% |
| Current drawdown | -51.4% | -32.4% |
| Annualized volatility | 54% | 93.5% |
| Value at risk (95%) | -4.9% | -9% |
Straight answers
Each answer is regenerated from the current snapshot, not written once and left to age.
Which is better, IRTC or PACB?
On the Algovestiq AIQ Score, PACB is the stronger of the two as of Nov 18, 2026, scoring 48 against IRTC's 44. The edge comes from momentum. IRTC is not without a case — it holds the better quality profile, which matters more if that is the objective you are optimizing for. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.
Is IRTC or PACB the better buy right now?
PACB carries the stronger systematic profile as of Nov 18, 2026, and the comparison is rated Fragile — 3 of 6 covered evidence groups agree. A Fragile rating means the conclusion is sensitive: the AIQ gap is narrow at 4 points. Treat the lead as provisional.
Why does the AIQ Score favor PACB over IRTC?
The composite weights Quality, Value, Momentum and Risk Resilience. PACB leads Momentum by 50 points; IRTC leads Quality by 26 points; IRTC leads Value by 20 points. Where the two split, the factor with the larger weight carries the result.
Which has more analyst upside, IRTC or PACB?
Analyst price targets imply +86.6% upside for IRTC and +5.2% for PACB, so the Street currently favors IRTC. That points the opposite way to the AIQ Score, which favors PACB. The two are measuring different things: the model reads current fundamentals, valuation, trend and risk; the Street is pricing forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something the analysts have already priced — it is the single most useful row on this page to investigate. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.
Which is better value, IRTC or PACB?
IRTC is the better-valued of the two on the peer-relative Value factor. IRTC on the peer-relative Value factor, by 20 points. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.
Which has stronger growth, IRTC or PACB?
PACB on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.
Which has stronger momentum, IRTC or PACB?
PACB on the Momentum factor, by 50 points. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.
Which is riskier, IRTC or PACB?
IRTC is the more resilient of the two, so the other name carries the higher downside risk. IRTC on Risk Resilience, by 20 points. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.
Is IRTC more profitable than PACB?
The profitability evidence is mixed: gross margin 72.3% vs 34.5%; operating margin -4.5% vs -99.6%; ttm roe -16.9% vs 61.7%. IRTC leads on two measures and PACB on one measure, and there is no single profitability composite that resolves the split — which of the two reads as "more profitable" depends on whether you weight pricing power or operating leverage.
Is PACB's lead over IRTC getting stronger or weaker?
PACB lead: Reversed — IRTC led by 10 AIQ points 30 sessions ago; PACB now leads by 4. This is measured from 120 daily comparison snapshots between 2026-06-01 and 2026-11-18. The lead has changed hands once in that window, most recently on 2026-11-13, when PACB moved ahead of IRTC.
What would change the IRTC vs PACB verdict?
The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: IRTC closes the Momentum gap — currently 50 points behind, the largest single contributor to PACB's edge; IRTC's Death Cross Active resolves — a bearish trend rule currently active against it; PACB's conflicting signal state resolves bearish — it currently carries 3 bullish and 3 bearish rules at once; a market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.
What do the current signals say about IRTC and PACB?
IRTC: 0 bullish / 3 bearish / 1 neutral. PACB: 3 bullish / 3 bearish / 1 neutral, conflicted. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on IRTC is Death Cross Active (bearish, long horizon). On PACB it is Golden Cross Active (bullish, long horizon).
Compare IRTC and PACB with others
Continue your research
This page answers which of the two. These answer the questions on either side of it.
How this comparison is scored
The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.
The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.
How to use side-by-side comparison →This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.